Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Applied Multivariate Statistical Analysis.
Johnson, A. R., & Wichern, D. W. (1988) · Biometrics · doi:10.2307/2531616 · Cited by 11,353
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Applied Multivariate Statistical Analysis
Härdle, W., & Simar, L. (2003) · Springer eBooks · doi:10.1007/978-3-662-05802-2 · Cited by 2,263
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Cited by
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
“Patient material CSF samples were obtained by lumbar puncture following standard procedures, collected in polypropylene tubes, and immediately frozen at −80°C until use (36, 38).”
MethodSelf-citationDiagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358
“In a series of 100 autopsy-confirmed dementia patients, clinical diagnosis at first visit was straightforward and correct in 68% of the cases [6].”
BackgroundMethodSelf-citationKoenig, A. M., Mechanic-Hamilton, D., Xie, S. X., Combs, M. F., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000202 · Cited by 350
Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 335
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu-Gaya, L., Lantero-Rodriguez, J., Pascoal, T. A., Suárez-Calvet, M., Rosa-Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 329
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationBiochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300
Self-citationSchindler, S. E., Galasko, D., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez-Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh-Momoh, C., Weiss, J., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00977-5 · Cited by 290
Self-citationDubois, B., von Arnim, C. A. F., Burnie, N., Bozeat, S., & Cummings, J. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01314-6 · Cited by 288
Brouwers, N., Van Cauwenberghe, C., Engelborghs, S., Lambert, J.-C., Bettens, K., Le Bastard, N., Pasquier, F., Montoya, A. G., Peeters, K., Mattheijssens, M., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.24 · Cited by 227
“Seemingly, the increased CSF Aβ 1−42 contradicts with the decreased CSF Aβ 1−42 levels that are considered indicative of AD in dementia patients and predictive in elderly people with or without mild cognitive impairment”
BackgroundSelf-citationFluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“First, most biomarker studies are based on clinically diagnosed cases, which introduces a relatively large percentage of misdiagnosis (Forman et al. 2006; Engelborghs et al. 2008).”
BackgroundCSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182
“There are only three CSF biomarker studies with moderate [15] to large numbers ([100) of subjects with neuropathologically confirmed diagnoses [9, 59].”
BackgroundTau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P.-J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · cclm · doi:10.1515/cclm.2011.086 · Cited by 167
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
“Other studies have suggested an assay using A 42 and T-tau levels can accurately discriminate AD from controls by means of a discrimination line, which has been validated in clinical practice [113] and in autopsy-confirmed patients, with sensitivity levels of 100% and specificity of 91% [114].”
ResultSleegers, K., Bettens, K., De Roeck, A., Van Cauwenberghe, C., Cuyvers, E., Verheijen, J., Struyfs, H., Van Dongen, J., Vermeulen, S., Engelborghs, S., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.013 · Cited by 106
“In comparison, a CSF biomarker panel comprising Ab1–42 and T-tau and P-tau181P can discriminate autopsy-confirmed AD from cognitively healthy elderly with a sensitivity of 86% and a specificity of 89% [28].”
Self-citationPreanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99
Latimer, C. S., Shively, C. A., Keene, C. D., Jorgensen, M. J., Andrews, R. N., Register, T. C., Montine, T. J., Wilson, A. M., Neth, B. J., Mintz, A., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3057 · Cited by 98
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
“Finally, to our knowledge the only additional studies utilizing autopsy-confirmed FTLD cohorts included a small number of FTLD cases (<10) in a non-AD category, with no direct comparison of FTLD and AD (Engelborghs et al., 2008; Tapiola et al., 2009; Schoonenboom et al., 2012).”
InfluentialIncreased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels
Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85
“The samples were collected at the Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken according to a standard protocol [2,25].”
Self-citationUllah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
No correlation between time‐linked plasma and CSF Aβ levels
Le Bastard, N., Aerts, L., Leurs, J., Blomme, W., De Deyn, P. P., & Engelborghs, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.08.006 · Cited by 59
“CSF Ab1–42 concentrations were significantly lower in AD patients compared to all the other diagnostic groups, as described previously (Andreasen and Blennow, 2005; Engelborghs et al., 2008; Sonnen et al., 2008).”
MethodResultSelf-citationVermeiren, Y., Le Bastard, N., Van Hemelrijck, A., Drinkenburg, W. H., Engelborghs, S., & De Deyn, P. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.06.010 · Cited by 56
“simplified the differential diagnosis between AD and nonAD patients and between control subjects and dementia patients with a specificity and sensitivity of approximately 80% up to 90%, considering neuropathological diagnosis as the “gold standard” [29].”
BackgroundSelf-citationAlzheimer's disease: cerebral glaucoma?
Wostyn, P., Audenaert, K., & De Deyn, P. P. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2009.12.019 · Cited by 51
Gossye, H., Van Broeckhoven, C., & Engelborghs, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00757 · Cited by 34
Self-citationNiemantsverdriet, E., Feyen, B. F. E., Le Bastard, N., Martin, J.-J., Goeman, J., De Deyn, P. P., Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170927 · Cited by 19
“The standard AD CSF biomarker panel that consists of amyloid- of 42 amino acids (A 1–42), total tau protein (T-tau), and hyperphosphorylated tau (P-tau), increases the diagnostic accuracy for AD [2], also in its prodromal phase [3], and is used in daily clinical practice [4].”
BackgroundSelf-citation
Metadata
- Authors
- Engelborghs, S., De Vreese, K., Van de Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., Martin, J.-J., Vanmechelen, E., & De Deyn, P. P.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 29
- Issue
- 8
- Pages
- 1143-1159
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2148445845
- Cited by
- 257
- References
- 36
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.